Loading the section…

ANAB: financial statements from SEC — TradeAlmanac

ANAB

AnaptysBio, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	26M	76M	22M	28M	30M	11M
Research and development	—	31M	38M	41M	42M	42M
Selling, general and administrative	26M	10M	11M	14M	11M	9M
Operating expenses	60M	42M	48M	55M	53M	51M
Operating income	−35M	35M	−26M	−28M	−23M	−40M
Pre-tax income	−53M	15M	−39M	−39M	−33M	−47M
Income tax	40,000	0	39,000	44,000	0	9,000
Net income	−53M	15M	−39M	−39M	−33M	−47M
Earnings per share	−1.84	0.54	−1.34	−1.28	−1.14	−1.71
Earnings per share, diluted	−1.84	0.52	−1.34	−1.28	−1.14	−1.71
Weighted average shares	29M	28M	29M	31M	29M	27M
Weighted average shares, diluted	29M	29M	29M	31M	29M	27M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	248M	238M	110M	44M	99M	123M	192M	72M
Receivables	26M	34M	76M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−26M	−11M
Depreciation and amortisation	130,000	146,000
Share-based compensation	14M	9M
Capital expenditure	17,000	35,000
Investing cash flow	35M	15M
Share buybacks	0

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator